ART6043

DRUG2 trials

Sponsors

Artios Pharma Limited, Artios Pharma Ltd

Conditions

Advanced Solid TumorAdvanced solid tumorsMetastatic Solid TumorMetastatic solid tumors

Phase 1

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Active, not recruitingNCT05898399

Artios Pharma LtdAdvanced Solid Tumor, Metastatic Solid Tumor

Start: 2023-06-30End: 2026-12-14Target: 220Updated: 2025-10-15

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

Not yet recruitingCTIS2023-509220-17-00

Artios Pharma LimitedAdvanced solid tumors, Metastatic solid tumors

Target: 55Updated: 2025-06-12

Related Papers

Abstract 3149: Micronuclei (MN) dynamics in preclinical models and in patient reticulocytes as a pharmacodynamic biomarker for the first in class DNA polymerase theta (PolΘ) inhibitor ART6043

Cancer Research2026-04-03

Abstract 2916: DNA polymerase theta inhibitor, ART6043, potentiates the efficacy of 177Lu- and 225Ac-based radioligand therapies in vitro and in vivo

Cancer Research2025-04-21